NCT04341181 2025-07-25
ProTarget
Rigshospitalet, Denmark
Phase 2 Recruiting
Clinical Trials
8 trialsNCT02091141 2024-07-23
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 2 Completed
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT01088815 2019-04-26
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01174264 2017-05-19
Evaluation of Food Effect on Pharmacokinetics of Vismodegib
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01546519 2016-05-23
A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function
Genentech, Inc.
Phase 1 Completed
NCT01096732 2014-01-08
HIPPoS
Cambridge University Hospitals NHS Foundation Trust
Phase 2 Terminated
NCT01713218 2012-10-24
NEOPACHI-001
Erasme University Hospital
Phase EARLY_PHASE1 Unknown